Conference Day 2
Thursday October 12, 2023

8:30 am
Morning Welcome Coffee

9:25 am Chair’s Opening Remarks

Optimizing the Immunogenicity of mRNA Cancer Vaccines: Maximizing Effectiveness & Minimizing Side Effects in Cancer Treatment

9:30 am Improving the Toxicity of mRNA Cancer Vaccines to Ensure Patients Safety


  • How by modifying the mRNA molecules themselves, we can reduce the toxicity
  • Reviewing alternative delivery systems to improve the toxicity of mRNA cancer vaccines
  • Exploring the current research into how we can enhance the immunogenicity and toxicity of these mRNA cancer vaccines to ensure safety and efficacy

10:00 am Opportunities to Further Control & Improve mRNA Cancer Vaccines


  • Optimization of vaccine delivery methods and schedules
  • Development of combination therapies with other cancer treatments
  • Identification and targeting of specific cancer antigens for improved efficacy

10:30 am Reviewing the Role of Lipid Nanoparticles in Enhancing the Effectiveness of mRNA Cancer Vaccines


  • Discussing the advancements of using LNP’s for mRNA Cancer vaccines to improve the research in the uptake and processing of the vaccine by the body, leading to a better immune response and greater efficacy
  • Revealing the new techniques that have been developed to reduce the risk of degradation and increase the longevity of LNPs in storage
  • Investigating the latest advances in storage of LNP’s to increase safety and global accessibility

11:00 am
Morning Break & Networking

12:00 pm Roundtable: Understanding the Standards & Regulatory Requirements for mRNA Cancer Vaccines
Moderator: Kun Zhuo

  • Kun Zhou Investigator, GeneLeap BioTechnology


  • How can we effectively show specificity and potency in mRNA cancer vaccines?
  • What are the best methods for testing potency in these vaccines and ensuring they are effective?
  • Which types of tumors are most responsive to this type of therapy, and how can we identify them?
  • Is it possible to start clinical trials with patients at an earlier diagnosis, and what are the potential implications of this approach?

12:30 pm Innovative Approaches to Cancer Acquired Resistance: Precision Immuno- Oncology and Synthetic Immune Lethality


  • Exploring how a combination of synthetic lethality with immunotherapy could form a new class of treatments to tackle acquired resistance in cancers.
  • Reviewing how these approaches hold significant potential in improving response rates and survival in cancer patients

1:00 pm Exploring Precision Dosing of mRNA Cancer Vaccines & Opportunities For Ways to Include Modeling & Simulation in mRNA Cancer Vaccine Development


  • Reviewing the use of computational models that can help predict immune responses to mRNA cancer vaccines and optimize dosing regimens.
  • Discuss how incorporating modeling and simulation can aid in reducing time and cost associated with mRNA cancer vaccine development
  • Understand how modeling and simulation can aid in successfully overcoming regulatory hurdles throughout mRNA vaccine development

1:30 pm
Lunch & Networking

Reviewing the Next Generation Techniques in Personalized mRNA Cancer Vaccines to Develop a More Effective Vaccine

2:30 pm A Review of the mRNA Cancer Vaccine Landscape


  • An exclusive overview of the current mRNA cancer vaccine drug and trial landscapes
  • Examining the properties of mRNA cancer vaccines and how they compare to the overall cancer vaccine space
  • Looking at the possible future directions of the mRNA cancer vaccine industry

3:00 pm Discussing the Future Possibilities Available With mRNA Cancer Vaccines

  • Karthik Musunuri Chief Executive Officer & Co-Founder, Avstera Therapeutics Inc.


  • Exploring ways of targeting the tumor cells in-vivo
  • Explaining whether you can target multiple tumors with the same vaccine
  • Looking into the future of where investments should go for mRNA cancer vaccines

3:30 pm The GoldspireTM Platform: A Personalized Biologic-Device Combination Approach to Generate Innate & Adaptive Anti-Tumor Immunity via Immunogenic Cell Death Mechanisms


  • Positive results seen in Phase 1b GBM trial
  • Phase 2b study is recruiting
  • Immunogenic cell death-associated markers in combination with evidence of anti-tumor immune responses in murine models and patient samples supports the underlying mechanism of action of GoldspireTM

4:00 pm End of the mRNA Cancer Vaccine Summit 2023